Director of Market Access, Gilead Sciences
Debbie Flanagan (BSC MSc PhD) is a Director of Market Access at Gilead Sciences Ltd. With >27 years’ experience across the pharmaceutical and diagnostic industry, she is passionate about shaping the policy and reimbursement landscape to ensure patients can access new and innovative therapies, spanning therapeutic areas such as HIV, Hepatitis C and Cell & Gene therapies. She is proud to have been involved in the collaborative approach taken by industry, NHSE and NHS Providers in enabling the initial establishment of CAR-T therapies in the UK. This has had a significant impact on patients living with diffuse large cell B Lymphoma and won an HSJ Partnership Award in 2020. Another significant achievement for Debbie was when Gilead won gold in the England Hepatitis C elimination tender – this ground-breaking partnership between NHSE & industry has made the elimination of an infectious blood borne virus a reality for many underserved and marginalised sectors of society. She is determined to continue to build on these successes and champion collaborative working with the system to ensure that optimal pathways are in place and all patients can benefit from innovative treatments.